JP2014080374A - イオントフォレーシス用組成物 - Google Patents
イオントフォレーシス用組成物 Download PDFInfo
- Publication number
- JP2014080374A JP2014080374A JP2012227314A JP2012227314A JP2014080374A JP 2014080374 A JP2014080374 A JP 2014080374A JP 2012227314 A JP2012227314 A JP 2012227314A JP 2012227314 A JP2012227314 A JP 2012227314A JP 2014080374 A JP2014080374 A JP 2014080374A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- iontophoresis
- hyaluronic acid
- composition
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 59
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 59
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 58
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000000600 disaccharide group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 12
- 210000003491 skin Anatomy 0.000 description 62
- 230000001186 cumulative effect Effects 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 230000037317 transdermal delivery Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 150000002016 disaccharides Chemical group 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229910021607 Silver chloride Inorganic materials 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 for example Chemical compound 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005370 electroosmosis Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- CKGQJOFAVYEVFG-KXQOOQHDSA-N 2-fluoro-4-[[(1R)-6-[2-[4-[1-(4-methoxyphenyl)-5-methyl-6-oxopyridazin-3-yl]triazol-1-yl]ethoxy]-1-methyl-1-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-3,4-dihydro-2H-isoquinolin-7-yl]oxy]benzoic acid Chemical compound COc1ccc(cc1)-n1nc(cc(C)c1=O)-c1cn(CCOc2cc3CCN[C@](C)(CC(=O)Nc4nccs4)c3cc2Oc2ccc(C(O)=O)c(F)c2)nn1 CKGQJOFAVYEVFG-KXQOOQHDSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MSPJNHHBNOLHOC-UHFFFAOYSA-N 3,3-dimethylcyclopropane-1,2-dicarboxylic acid Chemical compound CC1(C)C(C(O)=O)C1C(O)=O MSPJNHHBNOLHOC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- WHHGLZMJPXIBIX-UHFFFAOYSA-N decabromodiphenyl ether Chemical compound BrC1=C(Br)C(Br)=C(Br)C(Br)=C1OC1=C(Br)C(Br)=C(Br)C(Br)=C1Br WHHGLZMJPXIBIX-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- WPEXVRDUEAJUGY-UHFFFAOYSA-B hexacalcium;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OC1C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C1OP([O-])([O-])=O WPEXVRDUEAJUGY-UHFFFAOYSA-B 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- GBCAVSYHPPARHX-UHFFFAOYSA-M n'-cyclohexyl-n-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]methanediimine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1CCCCC1N=C=NCC[N+]1(C)CCOCC1 GBCAVSYHPPARHX-UHFFFAOYSA-M 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
【解決手段】本発明は、二糖単位−D−グルクロン酸−β−1,3−D−N−アセチルグルコサミン−β−1,4−が2つ結合したヒアルロン酸又はその塩を有効成分として含むイオントフォレーシス用皮膚外用剤組成物であって、当該組成物中でマイナスに荷電した当該ヒアルロン酸が、皮膚に流される電流との反発により経皮送達される、組成物である。
【選択図】図1
Description
[1]二糖単位−D−グルクロン酸−β−1,3−D−N−アセチルグルコサミン−β−1,4−が2つ結合したヒアルロン酸又はその塩を有効成分として含むイオントフォレーシス用皮膚外用剤組成物であって、当該組成物中でマイナスに荷電した当該ヒアルロン酸が、皮膚に流される電流との反発により経皮送達される、組成物。
[2]前記ヒアルロン酸の平均分子量が800以下である、[1]に記載のイオントフォレーシス用皮膚外用剤組成物。
[3]pHが3以上である、[1]又は[2]に記載のイオントフォレーシス用皮膚外用剤組成物。
[4]紫外線曝露された皮膚を処置するための、[1]〜[3]のいずれかに記載のイオントフォレーシス用皮膚外用剤組成物。
[5][1]〜[4]のいずれかに記載のイオントフォレーシス用皮膚外用剤組成物と、プラス極及びマイナス極の電極を備えたイオントフォレーシス用装置とを備えるイオントフォレーシス用キット。
[6][1]〜[4]のいずれかに記載のイオントフォレーシス用皮膚外用剤組成物を塗布した皮膚に、[4]に記載のイオントフォレーシス用装置のマイナス極を接触させ、当該マイナス極から電流を流す工程を含んで成る美容方法。
[7]紫外線曝露された皮膚を処置するための、[6]に記載の美容方法。
1-1.材料
HA4 (分子量 776.3 Da) は糖質科学研究所 (東京、日本) より供与された。その他の試薬は、市販の特級もしくはHPLC用のものを、和光純薬工業 (大阪、日本) より購入した。
雄性ヘアレスマウス (HR-1、7週令、体重:23-30 g) は、株式会社星野試験動物飼育所 (茨城、日本) より購入した。12時間ごとに明暗サイクル (on-off時間:7:00-19:00) を設定した部屋で飼育し、水と餌は自由に飽食可能とした。なお、動物実験は城西大学動物実験管理委員会の承諾を得て、「城西大学動物実験規定」に従い行った。
HA4水溶液は、精製水で0.50%の濃度に調製した。調製後の溶液のpHは約4であった。
ヘアレスマウス (8-10週令) を頸椎脱臼し、腹部の正中線を避けるように皮膚を摘出して、真皮側の脂肪を丁寧に取り除いた。In vitro皮膚透過試験には、全層皮膚を用いた。
摘出した皮膚は、有効透過面積1.77 cm2 (直径:1.5 cm) のFranz型拡散セルに、表皮をドナー側、真皮をレシーバー側にして装着した。電極にはAg/AgClを用い、プラス極からのIP (anodal IP) を負荷する際はドナー側にAg、レシーバー側にAgClを装置し、マイナス極からのIP (cathodal IP) を負荷する際はドナー側にAgCl、レシーバー側にAgを装置した。電極は特別仕様イオン導入器JN-78に接続し、電流は0.05、0.1 mA/cm2、デューティー比は90%に設定し、試験期間(6時間又は8時間)中連続的に負荷した。ドナー側に0.5% HA4水溶液1mLを、レシーバー側に生理食塩液5 mLを適用した。拡散セル内は32℃に保ち、スターラーで攪拌した。経時的にレシーバー液300μLをサンプリングし、その都度、同量の精製水を補充した。レシーバー液中のHA4を定量し、希釈分を補正して皮膚透過量を算出した。
各サンプルをメタノールと1:1で混合し、15,000×g、4℃、10分の条件で遠心分離して上清を回収した。上清は、LC/MS/MSで測定した。LC/MSシステムは、イオントラップ型タンデム質量分析装置 (LCQ DECA XP plus) (Thermo Fisher Scientific Inc.、MA、USA)およびポンプ (Paradigm MS4) (Microm Bioresources Inc.、CA、USA)、オートインジェクター (CTC HTS-PAL) (Microm Bioresources Inc.)、カラム (TSK-gel ODS-80Ts、2.0×150 mm) (TOSOH、東京、日本) から成り、移動相は10 mM酢酸アンモニウム水溶液:メタノール (8:2)、流速を100μL/minとし、ネガティブイオン化モードで検出した。
2-1. IPを用いたHA4の皮膚透過促進
上記試験方法に従い、HA4のCathodal IP負荷によるHA4の皮膚透過促進を、全層皮膚を用いて評価した。電流は0.1 mA/cm2に設定し、その他の条件については上述のとおりIP負荷を行なった。コントロールとして同一の組成物を当該皮膚に適用した(以降、受動拡散)。その結果、6時間後のHA4累積透過量は、受動拡散で0.3±0.1μg/cm2、0.1 mA/cm2 IP負荷で2310.7±703.1 μg/cm2となった。すなわち、IP負荷は、受動拡散と比較して約2700倍HA4皮膚透過量を増加させた。更に、透過係数は受動拡散で0.01 × 10-6cm/sであったのに対し、IP負荷ではその約3650倍の36.5 × 10-6cm/sであった。
Cathodal IPがHA4水溶液の皮膚透過促進効果に及ぼす影響について、Anodal IPと比較検討した。電流は0.1 mA/cm2に設定し、その他の条件については上述のとおりIP負荷を行なった。その結果、Anodal IP負荷から6時間後のHA4累積透過量は2.0±703.1 μg/cm2であり、これは同様の条件で2310.7±703.1 μg/cm2となったCathodal IP負荷(上記2-1.を参照のこと)の1/1155であった(図2)。また、Anodal IP負荷の透過係数は0.01 × 10-6cm/sであり、これは同様の条件で36.5 × 10-6cm/sであったCathodal IP負荷(上記2-1.を参照のこと)の約1/3650であった。
電流の変化がHA4水溶液の皮膚透過促進に及ぼす影響について検討した。検討する電流は上記試験の0.1 mA/cm2に加え、0.05 mA/cm2を採用した。その他の条件は上述のものを使用した。各電流を用いてCathodal IPを行なった結果、6時間後のHA4累積透過量は0.05 mA/cm2の場合に797.9 ±0.1μg/cm2、そして0.1 mA/cm2の場合に2310.7±703.1 μg/cm2となった(図3)。また、透過係数は0.05 mA/cm2の場合に13.2 × 10-6cm/s、そして、0.1 mA/cm2の場合に36.5 × 10-6cm/sであった。すなわち、累積透過量及び透過係数は0.05 mA/cm2の場合と比較して0.1 mA/cm2の方が約3倍高い値を示した。
Claims (7)
- 二糖単位−D−グルクロン酸−β−1,3−D−N−アセチルグルコサミン−β−1,4−が2つ結合したヒアルロン酸又はその塩を有効成分として含むイオントフォレーシス用皮膚外用剤組成物であって、当該組成物中でマイナスに荷電した当該ヒアルロン酸が、皮膚に流される電流との反発により経皮送達される、組成物。
- 前記ヒアルロン酸の平均分子量が800以下である、請求項1に記載のイオントフォレーシス用皮膚外用剤組成物。
- pHが3以上である、請求項1又は2に記載のイオントフォレーシス用皮膚外用剤組成物。
- 紫外線曝露された皮膚を処置するための、請求項1〜3のいずれか1項に記載のイオントフォレーシス用皮膚外用剤組成物。
- 請求項1〜4のいずれか1項に記載のイオントフォレーシス用皮膚外用剤組成物と、プラス極及びマイナス極の電極を備えたイオントフォレーシス用装置とを備えるイオントフォレーシス用キット。
- 請求項1〜4のいずれか1項に記載のイオントフォレーシス用皮膚外用剤組成物を塗布した皮膚に、請求項4に記載のイオントフォレーシス用装置のマイナス極を接触させ、当該マイナス極から電流を流す工程を含んで成る美容方法。
- 紫外線曝露された皮膚を処置するための、請求項6に記載の美容方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012227314A JP2014080374A (ja) | 2012-10-12 | 2012-10-12 | イオントフォレーシス用組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012227314A JP2014080374A (ja) | 2012-10-12 | 2012-10-12 | イオントフォレーシス用組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2014080374A true JP2014080374A (ja) | 2014-05-08 |
Family
ID=50784923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012227314A Pending JP2014080374A (ja) | 2012-10-12 | 2012-10-12 | イオントフォレーシス用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2014080374A (ja) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| WO2023037909A1 (ja) * | 2021-09-09 | 2023-03-16 | 株式会社資生堂 | 二液型皮膚改善化粧料のための容器 |
| US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6413008A (en) * | 1987-06-12 | 1989-01-17 | Unilever Nv | Skin treatment composition |
| JPH01272511A (ja) * | 1988-04-21 | 1989-10-31 | Tokyo Sankei Kagaku:Kk | 化粧品用添加剤 |
| JP2006298850A (ja) * | 2005-04-21 | 2006-11-02 | Shiseido Co Ltd | イオントフォレーシスによるトラネキサム酸の経皮送達 |
| JP2007126453A (ja) * | 2005-10-07 | 2007-05-24 | Toshitsu Kagaku Kenkyusho:Kk | ヒアルロナン産生促進剤及びヒアルロナン分解抑制剤 |
| JP2007131547A (ja) * | 2005-11-08 | 2007-05-31 | Shiseido Co Ltd | イオントフォレーシスによる美容方法 |
| JP2008163006A (ja) * | 2006-12-04 | 2008-07-17 | Mandom Corp | 皮膚化粧料 |
| JP2011057607A (ja) * | 2009-09-09 | 2011-03-24 | Toshitsu Kagaku Kenkyusho:Kk | ヒアルロン酸およびヒアルロン酸オリゴを含有する組成物 |
| JP2011513481A (ja) * | 2008-03-13 | 2011-04-28 | バイオランド エルティディ | 低分子及び高分子ヒアルロン酸と楡根皮とから抽出した多糖類を含有する老化防止用組成物 |
-
2012
- 2012-10-12 JP JP2012227314A patent/JP2014080374A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6413008A (en) * | 1987-06-12 | 1989-01-17 | Unilever Nv | Skin treatment composition |
| JPH01272511A (ja) * | 1988-04-21 | 1989-10-31 | Tokyo Sankei Kagaku:Kk | 化粧品用添加剤 |
| JP2006298850A (ja) * | 2005-04-21 | 2006-11-02 | Shiseido Co Ltd | イオントフォレーシスによるトラネキサム酸の経皮送達 |
| JP2007126453A (ja) * | 2005-10-07 | 2007-05-24 | Toshitsu Kagaku Kenkyusho:Kk | ヒアルロナン産生促進剤及びヒアルロナン分解抑制剤 |
| JP2007131547A (ja) * | 2005-11-08 | 2007-05-31 | Shiseido Co Ltd | イオントフォレーシスによる美容方法 |
| JP2008163006A (ja) * | 2006-12-04 | 2008-07-17 | Mandom Corp | 皮膚化粧料 |
| JP2011513481A (ja) * | 2008-03-13 | 2011-04-28 | バイオランド エルティディ | 低分子及び高分子ヒアルロン酸と楡根皮とから抽出した多糖類を含有する老化防止用組成物 |
| JP2011057607A (ja) * | 2009-09-09 | 2011-03-24 | Toshitsu Kagaku Kenkyusho:Kk | ヒアルロン酸およびヒアルロン酸オリゴを含有する組成物 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6016024104; J. Dermatol. Sci., 2006, Vol.44, No.3, pp.169-171 * |
| JPN7016001708; フレグランスジャーナル, 2004, Vol.32, No.9, pp10-16 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US11911498B2 (en) | 2020-06-01 | 2024-02-27 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| WO2023037909A1 (ja) * | 2021-09-09 | 2023-03-16 | 株式会社資生堂 | 二液型皮膚改善化粧料のための容器 |
| JP2023039780A (ja) * | 2021-09-09 | 2023-03-22 | 株式会社 資生堂 | 二液型皮膚改善化粧料のための容器 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6377385B2 (ja) | 生体組織貼付用キット及び生体組織貼付用パッチ | |
| CN108685759B (zh) | 一种透明质酸类物质和四氢嘧啶类物质的组合物 | |
| US7427273B2 (en) | Skin beautification cosmetic system using iontophoresis device, ultrasonic facial stimulator, and cosmetic additive | |
| US20200254241A1 (en) | Electrical method of delivering hyaluronic acid through the skin | |
| CN112190503A (zh) | 具有促渗透作用的透明质酸组合物、制备方法及其应用 | |
| KR101609104B1 (ko) | 경피 전달용 하이드로겔 패치 조성물, 이를 포함하는 경피 전달용 하이드로겔 패치 및 이의 제조방법 | |
| US11224566B2 (en) | Composition comprising a crosslinked hyaluronic acid (HA) in combination with a low-molecular HA and/or an agent stimulating endogenous HA synthesis | |
| JP2014080374A (ja) | イオントフォレーシス用組成物 | |
| US20090221985A1 (en) | System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof | |
| CH705713B1 (de) | Dermokosmetische Zusammensetzung zur topischen Anwendung. | |
| WO2008102349A2 (en) | Terbinafine formulation for iontophoresis | |
| CN115721582A (zh) | 一种含有外泌体的抗衰老精华液及其制备方法 | |
| Liang et al. | A wearable iontophoresis enables dual-responsive transdermal delivery for atopic dermatitis treatment | |
| KR101468579B1 (ko) | 약물 또는 활성물질의 안정성을 향상시키는 속용성 필름조성물, 속용성 필름 제제 및 이를 이용한이온영동패취세트 | |
| JP4768404B2 (ja) | イオントフォレーシスによる美容方法 | |
| WO2019185168A1 (en) | Electroporation of hyaluronic acid and heating | |
| RU2736504C1 (ru) | Система энхансеров трансдермального переноса и косметические композиции на ее основе | |
| WO2024200510A1 (en) | Haematococcus extract skin care composition | |
| JP4860940B2 (ja) | イオントフォレーシスによるトラネキサム酸の経皮送達 | |
| Nicoli et al. | Transdermal delivery of aminoglycosides: Amikacin transport and iontophoretic non-invasive monitoring | |
| CN116459177A (zh) | 一种含有水解海绵的化妆品组合物及其制备方法 | |
| JP2007130076A (ja) | 水溶性薬剤の経皮送達促進 | |
| Khalid et al. | Anti-Aging topical peptides and proteins | |
| Shemer | Onychomycosis and Iontophoresis | |
| CN120392632B (zh) | 一种具有高透皮性能的牛乳纳米囊泡装载物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150909 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150907 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161206 |